NCT04588922
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04588922
Title Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Sellas Life Sciences Group
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.